Background: Recently, the potential therapeutic effect of direct hemoperfusion with a polymyxin B-immobilized fiber column (PMX-DHP) has been reported for acute exacerbation of interstitial pneumonia (AE-IP), a highly morbid clinical event; however, there is no consensus on the appropriate procedure for PMX-DHP. We examined the appropriate perfusion duration of PMX-DHP for AE-IP. Methods: AE-IP patients receiving PMX-DHP were divided into two groups: short-duration group (≤6 h) (n = 5) and long-duration group (12 h) (n = 12). Results: ThePaO2/FiO2 (P/F) ratio increased immediately after PMX-DHP in the two groups. In the long-duration group, the P/F ratio continued to increase over the following 7 days, while, in the short-duration group, the P/F ratio declined again 3 days after therapy. The survival rate 30 days after PMX-DHP was significantly higher in the long-duration group than in the short-duration group. Conclusions: A long perfusion duration of PMX-DHP is more efficacious for AE-IP than a short perfusion duration.

Keywords:
Acute exacerbation, Idiopathic pulmonary fibrosis, Interstitial pneumonia, PMX-DHP
1.
Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K: Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathological findings in three cases. Chest 1993;103:1808–1812.
2.
Ambrosini V, Cancellieri A, Chilosi M, Zompatori M, Trisolini R, Saragoni L, Poletti V: Acute exacerbation of idiopathic pulmonary fibrosis: report of a series. Eur Respir J 2003;22:821–826.
3.
Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK, IPF Study Group: The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:963–967.
4.
Kim DS, Park JH, Park BK, Lee JS, Nicholson AG, Colby T: Acute exacerbation of idiopathic pulmonary fibrosis; frequency and clinical features. Eur Respir J 2006;27:143–150.
5.
Hyzy R, Huang S, Myers J, Flaherty K, Martinez F: Acute exacerbation of idiopathic pulmonary fibrosis. Chest 2007;132:1652–1658.
6.
Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, Raghu G, Roman J, Ryu JH, Zisman DA, Hunninghake GW, Colby TV, Egan JJ, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kondoh Y, Lynch DA, Müller-Quernheim J, Myers JL, Nicholson AG, Selman M, Toews GB, Wells AU, Martinez FJ, Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators: Acute exacerbations of idiopathic pulmonary fibrosis.Am J Respir Crit Care Med 2007;176:636–643.
7.
Churg A, Müller NL, Silva CI, Wright JL: Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg Pathol 2007;31:277–284.
8.
Park IN, Kim DS, Shim TS, Lim CM, Lee SD, Koh Y, Kim WS, Kim WD, Jang SJ, Colby TV: Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 2007;132:214–220.
9.
Silva CI, Müller NL, Fujimoto K, Kato S, Ichikado K, Taniguchi H, Kondoh Y, Johkoh T, Churg A: Acute exacerbation of chronic interstitial pneumonia: high-resolution computed tomography and pathologic findings. J Thorac Imaging 2007;22:221–229.
10.
Suda T, Kaida Y, Nakamura Y, Enomoto N, Fujisawa T, Imokawa S, Hashizume H, Naito T, Hashimoto D, Takehara Y, Inui N, Nakamura H, Colby TV, Chida K: Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med 2009;103:846–853.
11.
Miyazaki Y, Tateishi T, Akashi T, Ohtani Y, Inase N, Yoshizawa Y: Clinical predictors and histologic appearance of acute exacerbations in chronic hypersensitivity pneumonitis. Chest 2008;134:1265–1270.
12.
Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri VM, Ronco C: Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007;11:R47.
13.
Tsushima K, Kubo K, Yoshikawa S, Koizumi T, Yasuo M, Furuya S, Hora K: Effects of PMX-DHP treatment for patients with directly induced acute respiratory distress syndrome. Ther Apher Dial 2007;11:138–145.
14.
Tsushima K, Kubo K, Koizumi T, Yamamoto H, Fujimoto K, Hora K, Kan-nou Y: Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory distress syndrome. J Clin Apher 2002;17:97–102.
15.
Nakamura T, Kawagoe Y, Matsuda T, Shoji H, Ueda Y, Tamura N, Ebihara I, Koide H: Effect of polymyxin B-immobilized fiber on blood metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in acute respiratory distress syndrome patients. Blood Purif 2004;22:256–260.
16.
Kushi H, Miki T, Okamoto K, Nakahara J, Saito T, Tanjoh K: Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit Care 2005;9:R653–R661.
17.
Enomoto N, Suda T, Uto T, Kato M, Kaida Y, Ozawa Y, Miyazaki Y, Kuroishi S, Hashimoto D, Naito T, Fujisawa T, Matsui T, Inui N, Nakamura Y, Sato J, Mizuguchi T, Kato A, Chida K: Possible therapeutic effect haemoperfusion with a polymyxin B immobilized fibre column (PMX-DHP) on pulmonary oxygenation in acute exacerbation of interstitial pneumonia. Respirology 2008;13:452–460.
18.
Seo Y, Abe S, Kurahara M, Okada D, Saito Y, Usuki J, Azuma A, Koizumi K, Kudoh S: Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfusion treatment on acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2006;45:1033–1038.
19.
Noma S, Matsuyama W, Mitsuyama H, Suetsugu T, Koreeda Y, Mizuno K, Higashimoto I, Kakihana Y, Hashiguchi T, Maruyama I, Osame M, Arimura K: Two cases of acute exacerbation of interstitial pneumonia treated with polymyxin B-immobilized fiber column hemoperfusion treatment. Internal Med 2007;46:1447–1454.
20.
Kakugawa T, Mukae H, Saito M, Ishii K, Ishimoto Y, Sakamoto N, Takazono T, Fukuda Y, Ooe N, Kohno S: Rapidly progressive internal pneumonia associated with clinically amyopathic dermatomyositis successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intern Med 2008;47:785–790.
21.
American Thoracic Society; European Respiratory Society: American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277–304.
22.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–324.
23.
Bohan A, Peter JB: Polymyositis and dermatomyositis. 1. N Engl J Med 1975;292:344–347.
24.
Yoshizawa Y, Ohtani Y, Hayakawa H, Sato A, Suga M, Ando M: Chronic hypersensitivity pneumonitis in Japan: a nationwide epidemiologic survey. J Allergy Clin Immunol 1999;103:315–320.
25.
Hayakawa H, Shirai M, Sato A, Yoshizawa Y, Todate A, Imokawa S, Suda T, Chida K, Tamura R, Ishihara K, Saiki S, Ando M: Clinicopathological features of chronic hypersensitivity pneumonitis. Respirology 2002;7:359–364.
26.
Yamashita C, Takasaki Y: Is extended duration of direct hemoperfusion with polymyxin B-immobilized fiber (PMX-F) an appropriate or inappropriate treatment in sepsis patients? (In Japanese) ICU & CCU 2007;31:427–435.
27.
Yamashita C, Fujikawa T, Takechi K, Takasaki Y, Nitta K: Clinical efficacy of long-term treatment with PMX-DHP. (In Japanese) ICU & CCU 2005;29:557–566.
28.
Naka T, Shinozaki M, Akizawa T, Shima Y, Takaesu H, Nasu H: The effect of continuous veno-venous hemofiltration or direct hemoperfusion with polymyxin B-immobilized fiber on neutrophil respiratory oxidative burst in patients with sepsis and septic shock. Ther Apher Dial 2006;10:7–11.
29.
Tsujimoto H, Ono S, Hiraki S, Majima T, Kawarabayashi N, Sugasawa H, Kinoshita M, Hiraide H, Mochizuki H: Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16+ CD14+ monocytes in patients with septic shock. J Endotoxin Res 2004;10:229–237.
30.
Ono S, Tsujimoto H, Matsumoto A, Ikuta S, Kinoshita M, Mochizuki H: Modulation of human leukocyte antigen-DR, on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber. Am J Surg 2004;188:150–156.
31.
Abe S, Seo Y, Hayashi H, Matsuda K, Usuki J, Azuma A, Kudoh s, Gemma A: Nutrophil adsorption by polymyxin B-immobilized fiber column for acute exacerbation in patients with interstitial pneumonia: a pilot study. Blood Purif 2010;29:1–6.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.